Singapore markets closed
  • Straits Times Index

    3,240.06
    -4.49 (-0.14%)
     
  • S&P 500

    4,026.12
    -1.14 (-0.03%)
     
  • Dow

    34,347.03
    +152.93 (+0.45%)
     
  • Nasdaq

    11,226.36
    -58.94 (-0.52%)
     
  • BTC-USD

    16,210.16
    -328.86 (-1.99%)
     
  • CMC Crypto 200

    379.76
    -2.89 (-0.76%)
     
  • FTSE 100

    7,460.88
    -25.79 (-0.34%)
     
  • Gold

    1,761.60
    +7.60 (+0.43%)
     
  • Crude Oil

    74.09
    -2.19 (-2.87%)
     
  • 10-Yr Bond

    3.6910
    0.0000 (0.00%)
     
  • Nikkei

    28,162.83
    -120.20 (-0.42%)
     
  • Hang Seng

    17,297.94
    -275.64 (-1.57%)
     
  • FTSE Bursa Malaysia

    1,486.54
    0.00 (0.00%)
     
  • Jakarta Composite Index

    7,017.36
    -35.79 (-0.51%)
     
  • PSE Index

    6,681.47
    +74.53 (+1.13%)
     

Precision BioSciences to Participate in Upcoming Jefferies Cell & Genetic Medicine Summit

DURHAM, N.C., September 22, 2022--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the Jefferies Cell & Genetic Medicine Summit taking place September 29-30, 2022.

Details for the company presentation are as follows:
Date: Friday, September 30, 2022
Time: 2:00 PM ET
Location: Lotte New York Palace Hotel

The presentation will be available via a recorded webcast accessible on Precision’s website in the Investors section under Events & Presentations: https://investor.precisionbiosciences.com/events-and-presentations. An archived replay will be available for approximately 30 days following the event.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple ex vivo "off-the-shelf" CAR T immunotherapy clinical candidates and several in vivo gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220922005120/en/

Contacts

Investor Contact:
Mei Burris
Director, Investor Relations & Finance
Mei.burris@precisionbiosciences.com

Media Contact:
Maurissa Messier
Senior Director, Corporate Communications
Maurissa.Messier@precisionbiosciences.com